New Strategy Targets Drug-Resistant Prostate Cancer Using Genetics

An international research team has developed an innovative method to tackle cancers that have developed resistance to treatment, focusing on the mutations that enable these tumours to evade therapy. The Weizmann Institute of Science in Israel announced these findings, which were published in the journal Cancer Discovery.

A significant obstacle in cancer treatment is the phenomenon known as "treatment resistance." Many cancers, particularly those that have metastasised, initially respond well to various therapies such as hormone treatments, chemotherapy, and targeted drugs. However, as time passes, cancer cells can mutate and adapt, ultimately rendering these treatments ineffective.

Rather than attempting to obstruct the cancer's advancements, the researchers concentrated on the genetic mutations that emerge when tumours resist treatment. They found that these mutations leave distinct molecular markers, or fingerprints, on the cancer cells. To identify these fingerprints, the team created a sophisticated computer tool named SpotNeoMet, designed to analyse genetic data from tumours and detect resistance-related mutations that are prevalent across multiple patients.

These mutations generate small protein fragments known as neo-antigens. A key aspect of neo-antigens is that they are exclusive to cancer cells and absent in healthy cells, making them ideal targets for the immune system.

The strategy is to utilise these common neo-antigens to formulate new immunotherapies—treatments that empower the body’s immune system to identify and attack cancer cells without harming normal tissue. The researchers applied their method specifically to metastatic prostate cancer, a condition where most individuals eventually cease to respond to conventional treatments.

Using SpotNeoMet, the team identified three neo-antigens associated with drug resistance that were common among different patients. Laboratory experiments and animal studies demonstrated that these neo-antigens elicited immune responses specifically targeting cancer cells.

This discovery signifies a shift away from highly personalised cancer therapies, which are tailored for individual patients and can be costly and time-consuming to produce. Instead, this new approach aims to address resistance mutations found in a broader patient population, potentially benefiting larger groups suffering from difficult-to-treat cancers.

Researchers believe this strategy could also be adapted for other cancers that develop resistance to therapies. Although further research and clinical trials will be necessary before these treatments can be applied to human patients, experts consider this discovery a significant advancement towards more effective and versatile cancer therapies.